$9.26 (staying under $10 so it has a chance to go there...lol)
| |||
|
Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration
PR NewswireJune 19, 2019
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
CARLSBAD, Calif., June 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as "unexplained." The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
"Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions," said Bradley Robinson, CEO of Predictive Technology Group. "Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution."
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
"We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women," said Yan Zhang, general manager, reproductive health at Thermo Fisher. "With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment."
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Media Contact Information:
Mauricio Minotta
Director, Public Relations
+1 760 929 2456
Mauricio.minotta@thermofisher.com
Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com
PR NewswireJune 19, 2019
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
CARLSBAD, Calif., June 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as "unexplained." The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
"Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions," said Bradley Robinson, CEO of Predictive Technology Group. "Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution."
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
"We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women," said Yan Zhang, general manager, reproductive health at Thermo Fisher. "With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment."
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Media Contact Information:
Mauricio Minotta
Director, Public Relations
+1 760 929 2456
Mauricio.minotta@thermofisher.com
Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com
| |||
| |||
Predictive Technology Group Announces the Presentation of New Genetic Findings in Endometriosis at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology
Email Print Friendly Share
June 20, 2019 08:00 ET | Source: Predictive Technology Group, Inc.
SALT LAKE CITY, June 20, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Kenneth Ward, M.D. will present new genetic findings in endometriosis at the 2019 European Society of Human Reproduction and Embryology (ESHRE) meeting on Monday, June 24 in Vienna, Austria.
Dr. Ward is CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. Predictive Technology Group inlicensed the technology supporting its ARTGuide[SUP]®[/SUP] Test for endometriosis and other genetic causes of infertility from Juneau Biosciences and is Juneau Biosciences’ largest shareholder.
“Predictive is committed to understanding the biology, diagnosis and treatment of endometriosis,” said Bradley Robinson, President and CEO of Predictive Technology Group. “We are thrilled to contribute to the scientific understanding of a disease that has been difficult to treat and believe our investigative efforts will lead to improved patient outcomes in the future.”
Details on the presentation at ESRHE 2019 are as follows:
Abstract Title: Excess Germline Mutations in Four Genes in Unrelated Women with Surgical Endometriosis
Presenting Author: Dr. Kenneth Ward
| Presentation Details: | Monday, June 24 at 15:30 CEST |
| Session 23 | |
| Room: Strauss 1+2 |
About ESHRE
The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world's major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.
Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com or contact Investor Relations:
At the Company and Technical Questions
Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
Alert Price $4.60
Zack's Price Target
Members,
The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context, the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend, SP Biotechnology Select Industry Index has returned around 29%.
With time, biotechnology is emerging as a favored sector for investors with some risk appetite and looking for attractive returns.
We've just identified a small-cap biotech company with NASDAQ aspirations, zero debt, and several promising treatments in their pipeline.
Please turn your immediate attention to .
PRED operates through
Predictive Biotech
Predictive Laboratories
CellSure
Predictive Labs
The Predictive Biotech PB segment launched four products in 2017 and is currently generating quarterly revenues in excess of a $40 million annual run rate. Predictive Laboratories PL launched ARTguide in October 2018 for detecting genetic issues that may impact female fertility, including endometriosis and Fertility Dx in November, which adds a chromosomal microarray to the ARTguide diagnostic. In the future, PL will be responsible for advancing new candidates through the regulatory process. The third operating segment, CellSure CS, is responsible for obtaining the source material for the cellular therapy segment. The fourth segment is Predictive Labs PL and was created with the acquisition of Taueret Laboratories in March 2019. PL will launch genetic tests for endometriosis and degenerative disc disease in the coming quarters.
In their latest independent report, Zacks Small-Cap Research recently slapped a $8.00 price target on PRED, which equates to an upside of roughly 74% from today's alert price
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com Predrx.com Predictivebiotech.com and Predictivelabs.com.
Key reasons to own PRED shares
Pursuing a near-term NASDAQ listing
Rapidly growing cellular therapy segment
Competency in cell and tissue processing
Cash flow from Biotech supports development activities in Therapeutics
Advance of cellular therapy candidates through regulatory approval process in Therapeutics
Library of 300,000 DNA samples and 31 million-individual genealogy database
Multiple new products launching in the Laboratory segment
ARTguide
Fertility Dx
ENDORisk
Transform CellSure into dominant source of tissue product for both internal and external markets
Development platform that can be applied to many genetic tests and cellular therapy applications
The Bullish Case for PRED
Predictive Technologies is growing in a number of underserved areas of the market including cellular therapy and women s health, initially entering the market in the fertility health space. More specifically, the company emphasizes clinical categories of endometriosis, scoliosis, degenerative disc disease and regenerative human celland tissue products. The common theme that connects currently commercialized products is their reliance on the self-pay market. This is an attractive space as products do not require time consuming approval by formularies or face restrictions by managed care or pharmacy benefit managers that create a barrier between product and patient and layer on substantial distribution costs. Success in cellular therapy and fertility health are expected to support efforts to advance many of the in-development medicines and services through the regulatory process.
In contrast to many development companies, Predictive is free cash flow positive, which provides funds for new launches, research and development efforts and sales initiatives. While we expect the company will consume the majority of operational cash generated to support growth in the sales force for both cellular therapy and genetic diagnostic tests, we see less reliance on capital markets for the company to achieve its objectives than a pure development company.
Both cellular therapy and genetic diagnostic tests are emerging areas in the health care space. For companies that can source, process and provide high quality medicines to the physicians who administer them, there is substantial opportunity. The same goes for genetic diagnostic tests that are developed and backed up by a genealogy database that can accelerate genetic discoveries. Predictive ownership of a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples provides a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.
Predictive has identified a growth plan for each of its four segments. Predictive Biotech will continue to grow Section 361 product, which does not make any efficacy claims while Predictive Therapeutics will pursue Section 351 products that require review and approval from the FDA. CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, which was created and expanded through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.
PRED Plans to Uplist to NASDAQ
Predictive currently trades on the over the counter OTC markets and has submitted an application to the NASDAQ. The company received comments back from the NASDAQ in late May and expects to file responses in June. This action was preceded by the necessary prerequisite of filing of Form 10 in December 2018 and subsequent filings of the second and third quarter 10-Qs. The NASDAQ has several requirements regarding
number of shareholders, market makers, market value, asset value and share price among others. Predictive satisfies all of the requirements and may be uplisted to the exchange this month.
There are only a few days left in June, so a potential uplisting could trigger some significant FOMO. An uplisting to NASDAQ tends to signify a company that is experiencing strong growth.
Financial Results
Predictive Technology Group filed its fiscal third quarter 2019 financial statements on May 20, 2019 for the three month period ending March 31, 2019. The company reported revenues of $11.3 million, which was comprised almost entirely from the human cell and tissue products HCTPs segment. $10 thousand was generated in the Diagnostics and Therapeutics segment. Revenues increased 167% over 3Q18 levels. After cost of goods sold, gross profit was $6.5 million, representing a gross margin of 57.7%. Total operating expenses were $9.2 million, a 61% increase over the prior year. Operating loss fell to $5.0 million from $4.8 million in 3Q18 on increased headcount and higher research and development costs. On a per share basis, loss was $0.01. Cash balance as of March 31 was $1.8 million and no debt was carried on the balance sheet. For the first nine months of the fiscal year, cash from operations was $3.1 million, a sharp improvement from the $2.6 million deficit in the prior year. Property and equipment investments equaled $2.7 million, bringing free cash flow to $0.3 million for the first three quarters of FY19. Cash from financing activities was $1.7 million, resulting in a net increase in cash over the nine months of $0.6 million.
Zacks is estimating strong revenue increases in the years to come.
2018 Full Year Actual - $16.6M
2019 Full Year Estimate - $42M
2020 Full Year Estimate - $66.7M
2021 Full Year Estimate - $97.2M
Source
Latest News
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
Last Wednesday, Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., OTC PINK PRED focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as unexplained. The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology ACOG reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions, said Bradley Robinson, CEO of Predictive Technology Group. Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women, said Yan Zhang, general manager, reproductive health at Thermo Fisher. With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.
Market Outlook
Endometriosis affects an estimated 200 million women worldwide6 and is frequently misdiagnosed, preventing its early and proper treatment
30-50% of women with endometriosis may experience fertility issues
One of the leading causes of female infertility
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
No effective non-surgical method to diagnose
No therapeutic cure
Technical Analysis
We've done our and see the potential for a move of over 121%.
Perfect Wave 3 target to the 1.618 fibonacci extension now ready to target 2.618 fibonacci for wave 5
The Bottom Line
In our opinion, PRED has all of the characteristics of a winner in both the short and long term.
Strong Revenue Growth
Plans to uplist to the Nasdaq exchange
ZERO Debt
Strong Product Pipeline
Bullish Technicals
As such, we ask that all members start their research on PRED immediately, and consider building a position this morning at 930AM EST
Remember to use a or basic to protect your gains, as well as limit possible losses.
Best Regards,
The PennyStockLocks Team
Zack's Price Target
Members,
The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context, the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend, SP Biotechnology Select Industry Index has returned around 29%.
With time, biotechnology is emerging as a favored sector for investors with some risk appetite and looking for attractive returns.
We've just identified a small-cap biotech company with NASDAQ aspirations, zero debt, and several promising treatments in their pipeline.
Please turn your immediate attention to .
PRED operates through
Predictive Biotech
Predictive Laboratories
CellSure
Predictive Labs
The Predictive Biotech PB segment launched four products in 2017 and is currently generating quarterly revenues in excess of a $40 million annual run rate. Predictive Laboratories PL launched ARTguide in October 2018 for detecting genetic issues that may impact female fertility, including endometriosis and Fertility Dx in November, which adds a chromosomal microarray to the ARTguide diagnostic. In the future, PL will be responsible for advancing new candidates through the regulatory process. The third operating segment, CellSure CS, is responsible for obtaining the source material for the cellular therapy segment. The fourth segment is Predictive Labs PL and was created with the acquisition of Taueret Laboratories in March 2019. PL will launch genetic tests for endometriosis and degenerative disc disease in the coming quarters.
In their latest independent report, Zacks Small-Cap Research recently slapped a $8.00 price target on PRED, which equates to an upside of roughly 74% from today's alert price
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com Predrx.com Predictivebiotech.com and Predictivelabs.com.
Key reasons to own PRED shares
Pursuing a near-term NASDAQ listing
Rapidly growing cellular therapy segment
Competency in cell and tissue processing
Cash flow from Biotech supports development activities in Therapeutics
Advance of cellular therapy candidates through regulatory approval process in Therapeutics
Library of 300,000 DNA samples and 31 million-individual genealogy database
Multiple new products launching in the Laboratory segment
ARTguide
Fertility Dx
ENDORisk
Transform CellSure into dominant source of tissue product for both internal and external markets
Development platform that can be applied to many genetic tests and cellular therapy applications
The Bullish Case for PRED
Predictive Technologies is growing in a number of underserved areas of the market including cellular therapy and women s health, initially entering the market in the fertility health space. More specifically, the company emphasizes clinical categories of endometriosis, scoliosis, degenerative disc disease and regenerative human celland tissue products. The common theme that connects currently commercialized products is their reliance on the self-pay market. This is an attractive space as products do not require time consuming approval by formularies or face restrictions by managed care or pharmacy benefit managers that create a barrier between product and patient and layer on substantial distribution costs. Success in cellular therapy and fertility health are expected to support efforts to advance many of the in-development medicines and services through the regulatory process.
In contrast to many development companies, Predictive is free cash flow positive, which provides funds for new launches, research and development efforts and sales initiatives. While we expect the company will consume the majority of operational cash generated to support growth in the sales force for both cellular therapy and genetic diagnostic tests, we see less reliance on capital markets for the company to achieve its objectives than a pure development company.
Both cellular therapy and genetic diagnostic tests are emerging areas in the health care space. For companies that can source, process and provide high quality medicines to the physicians who administer them, there is substantial opportunity. The same goes for genetic diagnostic tests that are developed and backed up by a genealogy database that can accelerate genetic discoveries. Predictive ownership of a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples provides a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.
Predictive has identified a growth plan for each of its four segments. Predictive Biotech will continue to grow Section 361 product, which does not make any efficacy claims while Predictive Therapeutics will pursue Section 351 products that require review and approval from the FDA. CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, which was created and expanded through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.
PRED Plans to Uplist to NASDAQ
Predictive currently trades on the over the counter OTC markets and has submitted an application to the NASDAQ. The company received comments back from the NASDAQ in late May and expects to file responses in June. This action was preceded by the necessary prerequisite of filing of Form 10 in December 2018 and subsequent filings of the second and third quarter 10-Qs. The NASDAQ has several requirements regarding
number of shareholders, market makers, market value, asset value and share price among others. Predictive satisfies all of the requirements and may be uplisted to the exchange this month.
There are only a few days left in June, so a potential uplisting could trigger some significant FOMO. An uplisting to NASDAQ tends to signify a company that is experiencing strong growth.
Financial Results
Predictive Technology Group filed its fiscal third quarter 2019 financial statements on May 20, 2019 for the three month period ending March 31, 2019. The company reported revenues of $11.3 million, which was comprised almost entirely from the human cell and tissue products HCTPs segment. $10 thousand was generated in the Diagnostics and Therapeutics segment. Revenues increased 167% over 3Q18 levels. After cost of goods sold, gross profit was $6.5 million, representing a gross margin of 57.7%. Total operating expenses were $9.2 million, a 61% increase over the prior year. Operating loss fell to $5.0 million from $4.8 million in 3Q18 on increased headcount and higher research and development costs. On a per share basis, loss was $0.01. Cash balance as of March 31 was $1.8 million and no debt was carried on the balance sheet. For the first nine months of the fiscal year, cash from operations was $3.1 million, a sharp improvement from the $2.6 million deficit in the prior year. Property and equipment investments equaled $2.7 million, bringing free cash flow to $0.3 million for the first three quarters of FY19. Cash from financing activities was $1.7 million, resulting in a net increase in cash over the nine months of $0.6 million.
Zacks is estimating strong revenue increases in the years to come.
2018 Full Year Actual - $16.6M
2019 Full Year Estimate - $42M
2020 Full Year Estimate - $66.7M
2021 Full Year Estimate - $97.2M
Source
Latest News
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
Last Wednesday, Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., OTC PINK PRED focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as unexplained. The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology ACOG reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions, said Bradley Robinson, CEO of Predictive Technology Group. Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women, said Yan Zhang, general manager, reproductive health at Thermo Fisher. With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.
Market Outlook
Endometriosis affects an estimated 200 million women worldwide6 and is frequently misdiagnosed, preventing its early and proper treatment
30-50% of women with endometriosis may experience fertility issues
One of the leading causes of female infertility
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
No effective non-surgical method to diagnose
No therapeutic cure
Technical Analysis
We've done our and see the potential for a move of over 121%.
Perfect Wave 3 target to the 1.618 fibonacci extension now ready to target 2.618 fibonacci for wave 5
The Bottom Line
In our opinion, PRED has all of the characteristics of a winner in both the short and long term.
Strong Revenue Growth
Plans to uplist to the Nasdaq exchange
ZERO Debt
Strong Product Pipeline
Bullish Technicals
As such, we ask that all members start their research on PRED immediately, and consider building a position this morning at 930AM EST
Remember to use a or basic to protect your gains, as well as limit possible losses.
Best Regards,
The PennyStockLocks Team
LionStockAlertsDon't Want Anymore Emails? Unsubscribe
Hello!
Today, we would like to bring to your attention a new trade opportunity.
This under-the-radar company could be positioned for incredible growth in one of the fastest growing industries.
New Trade Alert: Predictive Technology Group Inc. (PRED)
Chances are you’ve heard of or even used services like 23 & Me and Ancestry DNA.
There is an incredible demand for services like these; not only from consumers, but from the entire healthcare industry.
However, this is bigger than understanding which part of the world your ancestors are from.
This is about your future health.
Understanding, identifying and treating diseases before they become problems is the next frontier in the healthcare industry.
But that’s not all…
What if you could get medication and healthcare services that are specially designed for your unique genetics?
These new approaches are helping biotech companies develop therapies that were thought to have been incurable just a few years ago.
U.S. dominated the genetic testing market in 2017 with the “world genetic testing market” “projected to surpass USD 22 billion by 2024”.
But that’s just part of the story.
According to the “latest research study”, “the global big data analytics in healthcare market was valued at $16.87 billion in 2017, and is projected to reach $67.82 billion by 2025, growing at a CAGR of 19.1% from 2018 to 2025.”
This new frontier in the healthcare industry is wide-open, creating what could be one of the biggest opportunities for companies that provide genetic diagnostics and data analytics in healthcare.
PRED could be one of the most overlooked opportunities we have seen in this sector.
PRED “is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention.”
PRED “has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression.”
PRED “uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.”
Operationally, PRED’scombination of “proprietary gene-based companion diagnostics” and “data analytics” expertise gives the company a potentially massive competitive advantage in the industry.
PRED demonstrated in its most recent earnings filing the phenomenal growth rate of the company:
“Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results”
- “Nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations”
- “I’m pleased to report our 10th consecutive quarter of sequential growth in revenue.”
- “Third quarter fiscal 2019 revenue of $11.3 million was up 167% over the third quarter of fiscal 2018”.
PRED “announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018.”
In addition, PRED has been recruiting industry veterans to lead its expansion.
As part of its commitment to strong stewardship, just a few weeks ago PRED named a 25-year veteran of the women’s health field, as detailed in this company statement:
“Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women’s health clinical franchise. Dr. Rabin has more than 25 years of experience in women’s healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.”
Not only that, but PRED has recently taken steps to put its biotech treatments through clinical trials, in a major step towards potential mass-market adoption.
PRED recently signed a “letter of intent with IQVIA” “to guide the regulatory strategy for its wholly owned subsidiary Predictive Biotech,” as detailed in this statement from the company:
“Specifically, IQVIA will guide Predictive Biotech in its U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application and subsequent clinical trial for osteoarthritis (OA) of the knee.”
“The Company expects to meet with the FDA during the third quarter of 2019 to discuss the submission of the IND with the objective of determining the safety and effectiveness of CoreCyte™ compared to a placebo control for [the] treatment of OA of the knee.”
“The Company will work with the FDA to determine if the FDA will accept the current safety data from over 75,000 patients previously treated with CoreCyte™.”
But why now? Why should you care?
As the company stated in it’s recent press release, “CoreCyte™ has the opportunity to address a significant unmet clinical need by providing an alternative to opioids, cortisone and/or hyaluronic injections for treating OA knee pain.”
In addition, the company recently announced that it “has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain.”
According to the National Institute on Drug Abuse, “every day, more than 130 people in the United States die after overdosing on opioids” while “roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them.”
“The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is $78.5 billion a year”.
This problem has created a new demand for non-opioid treatments for chronic pain and PRED could be one of the companies with the solution.
In addition to all of the above accomplishments, PRED has announced multiple breaking developments in the past few days.
Last week the company announced:
“Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration”
“Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally.”
This “global research collaboration” with Thermo Fisher Scientific is “focused on studying the genetic factors underlying infertility in women.”
“Worldwide, around 70 to 80 million couples currently experience infertility”.
PRED CEO Bradley Robinson stated the following regarding this breakthrough collaboration:
“Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions. Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next-generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.”
On Thursday, the company announced:
“Predictive Technology Group Announces the Presentation of New Genetic Findings in Endometriosis at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology”
“SALT LAKE CITY, June 20, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Kenneth Ward, M.D. will present new genetic findings in endometriosis at the 2019 European Society of Human Reproduction and Embryology (ESHRE) meeting on Monday, June 24 in Vienna, Austria.”
This presentation, which occurred today, could be another positive catalyst for PRED as more investors discover this opportunity.
But, that’s not all…
Just last month, PRED “completed the application and submitted the request to list Predictive on The NASDAQ Exchange.”
“The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards,” but it’s a sign of the company’s commitment to continued growth.
In the event that PRED can successfully accomplish this, they could position themselves in front of mainstream investors on Wall Street.
If all of the above wasn’t enough, PRED has a potentially remarkable chart setup and a history of experiencing massive gains.
PRED has seen a remarkable 2019, starting the year at 0.93 and rallying to a high of 6.91, upside of more than 643%.
Since this incredible rally, PRED has consolidated near its 20 day moving average (DMA) and could be positioned for another breakout higher.
PRED is an overlooked opportunity that has been growing at a remarkable pace and could be the solution for multiple high growth sectors within healthcare.
Make sure to do your own due diligence.
Happy Trading!
LionStockAlerts
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
Trading Rules [Please Review Before Taking Any Action]:
- Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb - if you cannot sleep at night as a consequence of your investment, then you have over invested.
- Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
- Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use "trailing stop %" or "trailing stop $" orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
- Cut losses quickly when day/swing trading. It's better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
- Actively manage all your investments & trade during market hours only.Trading during pre/post market hours carries greater volatility/risk.
Predictive Technology Group Announces the Presentation of New Data Demonstrating the Genetic Basis of Endometriosis at ESHRE
Email Print Friendly Share
June 25, 2019 08:00 ET | Source: Predictive Technology Group, Inc.
SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. The study data was discussed in an oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria.
The abstract of the presentation “Excess germline mutations in four genes in unrelated women with surgical endometriosis” is available at https://www.eshre.eu/ESHRE2019/Programme/Searchable#!abstractdetails/0000581010.
“Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group. “Our investment in technology has led to the identification of additional germline DNA changes associated with endometriosis.”
The study was conducted to identify genes in patients with endometriosis versus the general population. Whole exome sequencing was used to identify four genes (ZNF586, LUZP4, POP4 and UNC5CL) with significant gene burden in over 2,500 women with endometriosis, which was significant versus the general population (p<5 x 10-8). The four newly discovered mutated genes are all involved in the regulation of gene expression. Importantly, it was found that one in four women with endometriosis carry a mutation in one of these genes, while the population frequency is only 8%.
“Our research may lead to a better understanding of the pathophysiology of endometriosis,” said Dr. Ward, CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. “Given the pace of innovation for targeted therapy, we are thrilled to present clinically relevant insights that may result in improved treatment of infertility as a result of endometriosis.”
About Endometriosis
Endometriosis occurs when the endometrial tissue that lines the uterus grows outside of the uterus and onto other areas of the body. Symptoms include pelvic pain, heavy periods, pain during sexual intercourse or bowel movements and infertility. Endometriosis affects 1 in 10 women worldwide in the reproductive age group. This prevalence increases to 1 in 3 women with infertility and 1 in 2 women with a normal cycle whose partner has normal sperm.
About ESHRE
The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world's major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.
Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com or contact Investor Relations:
At the Company and Technical Questions
Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com
Investor Contact
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
HARRY BOXER, RAISES TARGET ON PRED TO 8.5 $9 AREA
https://www.thetechtrader.com/chart...stocktwits&utm_medium=social&utm_campaign=COD
https://www.thetechtrader.com/chart...stocktwits&utm_medium=social&utm_campaign=COD
Gotta hand it to the shorts. They dont die easy . So I posted the few websites that wrote up PRED , with one day promotions.
This newsletter is a paid advertisement We have been compensated fifteen thousand dollars by ACN LLC for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for PREDnt, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC
The write ups are beautiful they did a nice job. The question is , who paid for them? IT CERTAINLY WASN'T THE COMPANY . Why pay for any promotion when your days away from getting listed on NASDQ ?
Well, either a large shareholder paid for it to sell some stock , except there wasn't any blow off volume to show the selling, OR......
The shorts paid for it to LOOK like PRED was running a pump and dump. They then naturally trigger and inquiry from NASDQ to delay our listing . I believe the second scenario is much more likely.
Also with a holiday coming , and end of the month net cap requirements to meet, the timing is too perfect
This is a gift, if you thought you missed PRED, take advantage of this
3.85 WORST case IMO
This newsletter is a paid advertisement We have been compensated fifteen thousand dollars by ACN LLC for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for PREDnt, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC
The write ups are beautiful they did a nice job. The question is , who paid for them? IT CERTAINLY WASN'T THE COMPANY . Why pay for any promotion when your days away from getting listed on NASDQ ?
Well, either a large shareholder paid for it to sell some stock , except there wasn't any blow off volume to show the selling, OR......
The shorts paid for it to LOOK like PRED was running a pump and dump. They then naturally trigger and inquiry from NASDQ to delay our listing . I believe the second scenario is much more likely.
Also with a holiday coming , and end of the month net cap requirements to meet, the timing is too perfect
This is a gift, if you thought you missed PRED, take advantage of this
3.85 WORST case IMO
